PMID- 17093958
OWN - NLM
STAT- MEDLINE
DCOM- 20070907
LR  - 20071115
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 86
IP  - 2
DP  - 2007 Feb
TI  - Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in 
      the outcome over the last decade.
PG  - 127-32
AB  - Allogeneic hematopoetic stem cell transplantation (HSCT) is still the only 
      curative therapeutic option for chronic myelogenous leukemia (CML). To examine 
      the development of allogeneic HSCT at our center over the past two decades 
      (decade 1: 1984-1994; decade 2: 1995-2005), all CML patients transplanted in 
      first chronic phase (n = 234) were analyzed with respect to patient 
      characteristics, overall survival, transplant-related mortality (TRM), and 
      relapse incidence. The median follow up time was 54 months (range 1-218). The 
      incidence of acute graft vs host disease (GvHD) degrees II-IV and extensive 
      chronic GvHD were not different between the two decades (p = 0.894 and p = 0.422, 
      respectively). There was also no difference in the relapse incidence (23 vs 26%, 
      p = 0.869). One-year TRM and overall survival were improved in the later decade 
      (33 vs 18%, p = 0.011 and 62 vs 73% at 5 years, p = 0.063, respectively). The 
      major reason for improved outcome in decade 2 was the improved management of 
      acute GvHD and infections in the early phase after transplantation (p = 0.026). 
      In conclusion, the past decade has seen significant improvement in the 
      performance of allogeneic HSCT for CML.
FAU - Weisser, Martin
AU  - Weisser M
AD  - Clinical Cooperative Group for Haematopoetic Cell Transplantation, Department of 
      Medicine III, University of Munich, Klinikum Grosshadern and GSF-National 
      Research Center for Environment and Health, Munich, Germany. 
      martin.weisser@med.uni-muenchen.de
FAU - Ledderose, Georg
AU  - Ledderose G
FAU - Jochem Kolb, Hans
AU  - Jochem Kolb H
LA  - eng
PT  - Journal Article
DEP - 20061109
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/complications/immunology
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL 
      Positive/*epidemiology/immunology/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Survival Rate
MH  - Time Factors
MH  - Transplantation, Homologous/immunology
MH  - Treatment Outcome
EDAT- 2006/11/10 09:00
MHDA- 2007/09/08 09:00
CRDT- 2006/11/10 09:00
PHST- 2006/04/07 00:00 [received]
PHST- 2006/09/01 00:00 [accepted]
PHST- 2006/11/10 09:00 [pubmed]
PHST- 2007/09/08 09:00 [medline]
PHST- 2006/11/10 09:00 [entrez]
AID - 10.1007/s00277-006-0196-z [doi]
PST - ppublish
SO  - Ann Hematol. 2007 Feb;86(2):127-32. doi: 10.1007/s00277-006-0196-z. Epub 2006 Nov 
      9.